US Drug Recall Register
Class III · Low risk Terminated Initiated Feb 24, 2020 (7 years ago)

Zoledronic Acid Injection 5 mg/100 mL

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for impurities during stability testing.

What was recalled

Zoledronic Acid Injection 5 mg/100 mL (0.05 mg/mL), Solution for Intravenous Infusion, Sterile Solution, 100 mL Single - Dose Vial per Carton, Rx Only, Distributed by: Breckenridge Pharmaceutical, Inc., Boca Raton, FL 33487, Manufactured by: Pharmaceutics International, Inc., Hunt Valley, MD 21031, NDC 51991-064-98.

Recalling firm
Breckenridge Pharmaceutical, Inc
NDC code
51991-064-98
Origin
CT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1063-2020

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Zoledronic recalls

See all
Class III · Low risk Terminated

Zoledronic Acid Injection

Reason Failed Impurities/Degradation Specifications: OOS for unknown impurities.

Dr. Reddy's Laboratories, Inc. NDC 43598-331-11 D-0104-2019
Class III · Low risk Terminated

Zoledronic Acid Injection

Reason Failed Impurities/Degradation Specifications: OOS for unknown impurities.

Dr. Reddy's Laboratories, Inc. NDC 55111-688-52 D-0103-2019
Class II · Moderate risk Terminated

Zoledronic Acid Injection

Reason Lack of Assurance of Sterility; defective seals where the metal silver ring was not attached tightly to the vial

Dr. Reddy's Laboratories, Inc. NDC 55111-688-52 D-0784-2016
Class II · Moderate risk Terminated

Zoledronic Acid active pharmaceutical ingredient packaged in…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-958-2015